Movalis (Meloxicam)

Meloxicam, the active ingredient in Movalis, is a nonsteroidal anti-inflammatory drug (NSAID) presented as a tablet for oral use. It reduces inflammation and pain in conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and acute musculoskeletal pain.

GNH USA supplies Movalis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Movalis acts on inflammatory pathways to relieve pain and improve joint function in several rheumatic diseases. - Rheumatoid arthritis: decreases joint swelling, pain and stiffness, helping maintain mobility. - Osteoarthritis: alleviates chronic joint discomfort and improves functional ability. - Ankylosing spondylitis: reduces spinal stiffness and inflammatory pain. - Acute pain: provides short‑term relief of moderate nociceptive pain.

Common Side Effects: - Gastrointestinal upset (nausea, dyspepsia) - Headache - Dizziness - Elevated blood pressure - Peripheral edema - Skin rash

Serious or Rare Side Effects: - Gastrointestinal ulcer or bleeding - Severe liver injury (hepatitis, jaundice) - Acute kidney failure or worsening renal function - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Anaphylaxis or severe hypersensitivity reactions - Cardiovascular thrombotic events (myocardial infarction, stroke)

Before prescribing Movalis, clinicians should evaluate patient‑specific risk factors and monitor therapy. - Assess renal function: check kidney status prior to initiation and periodically thereafter. - Monitor hepatic enzymes: perform liver function tests during treatment. - Use caution in cardiovascular disease: consider increased risk of thrombotic events. - Avoid in known hypersensitivity to NSAIDs: discontinue immediately if allergic reaction occurs. - Limit use in elderly patients: higher incidence of gastrointestinal complications. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Meloxicam may interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened risk of serious bleeding. - ACE inhibitors or ARBs: potential reduction in renal function. - Lithium: increased serum lithium concentrations. Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): additive risk of gastrointestinal bleeding. - Diuretics: may affect blood pressure control and renal handling of electrolytes.